Leerink Partners Downgrades Caribou Biosciences to Market Perform, Lowers Price Target to $1

Benzinga Newsdesk www.benzinga.com Negative 91.6%

Neg 91.6% Neu 0% Pos 0%

Leerink Partners analyst Daina Graybosch downgrades Caribou Biosciences (NASDAQ:CRBU) from Outperform to Market Perform and lowers the price target from $4 to $1.